VYGR Voyager Therapeutics, Inc.Stock Price & Overview
$8.77
Charts
Quant Ranking
VYGR Analysis
VYGR News
Latest Headlines
Ratings Summary
People Also Follow
Similar to VYGR
ETFs Holding VYGR
VYGR Company Profile
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company’s lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer’s disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer’s disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer’s disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich’s ataxia; and GBA1 gene replacement to treat parkinson’s disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington’s disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
VYGR Revenue
VYGR Earnings Per Share
Earnings Estimates
Earnings Revisions
Valuation
Growth
Profitability
Momentum
Capital Structure
Dividends
VYGR Ownership
VYGR Peers
Risk
Technicals
VYGR Transcripts
Investor Presentations
VYGR SEC Filings
Press Releases
VYGR Income Statement
VYGR Balance Sheet
VYGR Cash Flow Statement
VYGR Long Term Solvency
Discover More
You may be interested in: